Hepatitis C Contagious
Links shared publicly online about this topic
Interview with the FDA on new Hepatitis C drugs | CurrentMedicine.tv
currentmedicine.tv — “July 28, 2011 The FDA's Director of new drugs, CDER, Dr. Janet Woodcock, discusses the two new drugs approved to treat, and now also cure, Hepatitis C:” View full resource at currentmedicine.tv
Most Recently Shared on July 29, 2011 at 1:30 pm By:
New Video: FDA discusses new Hep C drugs Victrelis (boceprevir) and Incivek (telaprevir) http://t.co/6RpWLQU
CDC: All Baby Boomers Should Undergo One-Time Screening for Hepatitis C - Physician's First Watch
firstwatch.jwatch.org — “The CDC is recommending one-time testing for hepatitis C in patients born between 1945 and 1965, regardless of the patients' risk for hepatitis, according to finalized guidelines published in MMWR. Patients who test positive . . . LINK(S):” View full resource at firstwatch.jwatch.org
Most Recently Shared on August 16, 2012 at 10:40 pm By:
CDC: All Baby Boomers Should Undergo One-Time Screening for Hepatitis C: http://t.co/J73bh44c #medicine #news
Two new targets could enhance the body's defenses against West Nile and hepatitis C
news-medical.net — “Two new targets have been discovered for antiviral therapies and vaccines strategies that could enhance the body's defenses against such infectious diseases as West Nile and hepatitis C. The targets are within the infection warning system inside living cells.” View full resource at news-medical.net
Most Recently Shared on July 31, 2012 at 6:44 am By:
Two new targets could enhance the body's defenses against West Nile and hepatitis C: Two new targets have been d... http://t.co/ZNmkxNlK
Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b–infected null responders - Chayama - 2012 - Hepatology - Wiley Online Library
www3.interscience.wiley.com — “Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b–infected null responders - Chayama - 2012 - Hepatology - Wiley Online Library” View full resource at www3.interscience.wiley.com
Most Recently Shared on February 25, 2012 at 5:34 am By:
Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease ... http://t.co/Lcil13Bo
Effective Approaches to HCV Screening
secure.quantiamd.com — “In this presentation, Dr. Alain Litwin discusses effective HCV screening interventions: identifying the risk factors, populations worth screening, and cost-effective screening methods. Learn about the VA as an excellent screening model, and finish with a brief discussion of referral after screening.” View full resource at secure.quantiamd.com
Most Recently Shared on July 17, 2012 at 12:27 pm By:
Advances in the treatment of #Hepatitis C: What you can do to prepare http://t.co/JAW0XHG7
Regulators accept Merck drug for expedited review - Bloomberg
bloomberg.com — “WHITEHOUSE STATION, N.J. (AP) --" Drug developer Merck & Co. said Thursday U.S. and European regulators accepted its potential hepatitis C treatment boceprevir for expedited review.” View full resource at bloomberg.com
Most Recently Shared on January 10, 2011 at 3:43 pm By:
Regulators accept Merck drug (Hep C) for expedited review - http://t.co/IQkO5TJ
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
Healthcare Channel
A multimedia source for business and policy information on the healthcare space.
-
Julie Bohlen
Health content professional with MBA in heathcare management. Sharing quality health resources and news. On executive team at OrganizedWisdom.
-
News-Medical.Net
Medical News from Around the World
Advertisement

